Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma

Hui Gan; Lawrence Cher; Po-Ling Inglis; Zarnie Lwin; Eddie Lau; Christian Wichmann; Uwe Ackermann; Alex McDonald; Ashray Gunjur; Nicole Coombs; Kirsten Remen; Nancy Guo; Sze-Ting Lee; Sylvia Gong; Jodie Palmer; Kunthi Pathmaraj; Graeme O'Keefe; Fiona Scott; Bryan Day; Andrew Boyd; Paul Thomas; Omar Ahmed; Dale Chappell; Cameron Durrant; Andrew Scott

Meeting ReportOral - PhysicianPharm

Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma

Hui Gan, Lawrence Cher, Po-Ling Inglis, Zarnie Lwin, Eddie Lau, Christian Wichmann, Uwe Ackermann, Alex McDonald, Ashray Gunjur, Nicole Coombs, Kirsten Remen, Nancy Guo, Sze-Ting Lee, Sylvia Gong, Jodie Palmer, Kunthi Pathmaraj, Graeme O'Keefe, Fiona Scott, Bryan Day, Andrew Boyd, Paul Thomas, Omar Ahmed, Dale Chappell, Cameron Durrant and Andrew Scott

Journal of Nuclear Medicine May 2021, 62 (supplement 1) 104;

Hui Gan

1Olivia Newton-John Cancer Research Institute, Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lawrence Cher

2Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Po-Ling Inglis

3Royal Brisbane and Womens Hospital Brisbane Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Zarnie Lwin

3Royal Brisbane and Womens Hospital Brisbane Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Eddie Lau

2Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Christian Wichmann

1Olivia Newton-John Cancer Research Institute, Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Uwe Ackermann

2Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alex McDonald

1Olivia Newton-John Cancer Research Institute, Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ashray Gunjur

2Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Nicole Coombs

2Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kirsten Remen

2Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Nancy Guo

1Olivia Newton-John Cancer Research Institute, Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sze-Ting Lee

1Olivia Newton-John Cancer Research Institute, Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sylvia Gong

2Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jodie Palmer

1Olivia Newton-John Cancer Research Institute, Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kunthi Pathmaraj

2Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Graeme O'Keefe

2Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Fiona Scott

1Olivia Newton-John Cancer Research Institute, Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Bryan Day

4QIMR Berghofer Medical Research Institute Brisbane Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Andrew Boyd

1Olivia Newton-John Cancer Research Institute, Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Paul Thomas

3Royal Brisbane and Womens Hospital Brisbane Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Omar Ahmed

5Humanigen Inc Burlingame CA United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Dale Chappell

5Humanigen Inc Burlingame CA United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Cameron Durrant

5Humanigen Inc Burlingame CA United States

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Andrew Scott

1Olivia Newton-John Cancer Research Institute, Austin Hospital Melbourne Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Info & Metrics

Article Information

vol. 62 no. supplement 1 104

Published By

Society of Nuclear Medicine

Print ISSN

0161-5505

Online ISSN

2159-662X

History

Published online May 18, 2021.

Author Information

Hui Gan₁,
Lawrence Cher₂,
Po-Ling Inglis₃,
Zarnie Lwin₃,
Eddie Lau₂,
Christian Wichmann₁,
Uwe Ackermann₂,
Alex McDonald₁,
Ashray Gunjur₂,
Nicole Coombs₂,
Kirsten Remen₂,
Nancy Guo₁,
Sze-Ting Lee₁,
Sylvia Gong₂,
Jodie Palmer₁,
Kunthi Pathmaraj₂,
Graeme O'Keefe₂,
Fiona Scott₁,
Bryan Day₄,
Andrew Boyd₁,
Paul Thomas₃,
Omar Ahmed₅,
Dale Chappell₅,
Cameron Durrant₅ and
Andrew Scott₁

¹Olivia Newton-John Cancer Research Institute, Austin Hospital Melbourne Australia
²Austin Hospital Melbourne Australia
³Royal Brisbane and Womens Hospital Brisbane Australia
⁴QIMR Berghofer Medical Research Institute Brisbane Australia
⁵Humanigen Inc Burlingame CA United States

Statistics from Altmetric.com

Cited By...

Citations
Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: May 2021 to February 2025

	Abstract	Full	Pdf
May 2021	53	0	0
Jun 2021	77	0	0
Jul 2021	42	0	0
Aug 2021	30	0	0
Sep 2021	48	0	0
Oct 2021	30	0	0
Nov 2021	22	0	0
Dec 2021	38	0	0
Jan 2022	53	0	0
Feb 2022	16	0	0
Mar 2022	51	0	0
Apr 2022	119	0	0
May 2022	50	0	0
Jun 2022	64	0	0
Jul 2022	29	0	0
Aug 2022	27	0	0
Sep 2022	24	0	0
Oct 2022	11	0	0
Nov 2022	39	0	0
Dec 2022	22	0	0
Jan 2023	27	0	0
Feb 2023	22	0	0
Mar 2023	41	0	0
Apr 2023	20	0	0
May 2023	27	0	0
Jun 2023	24	0	0
Jul 2023	28	0	0
Aug 2023	14	0	0
Sep 2023	17	0	0
Oct 2023	22	0	0
Nov 2023	26	0	0
Dec 2023	39	0	0
Jan 2024	39	0	0
Feb 2024	27	0	0
Mar 2024	36	0	0
Apr 2024	49	0	0
May 2024	32	0	0
Jun 2024	50	0	0
Jul 2024	98	0	0
Aug 2024	124	0	0
Sep 2024	34	0	0
Oct 2024	46	0	0
Nov 2024	41	0	0
Dec 2024	29	0	0
Jan 2025	36	0	0
Feb 2025	42	0	0

In this issue

Journal of Nuclear Medicine

Vol. 62, Issue supplement 1

May 1, 2021

Table of Contents
Index by author

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma

Journal of Nuclear Medicine May 2021, 62 (supplement 1) 104;

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma

Journal of Nuclear Medicine May 2021, 62 (supplement 1) 104;

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Info & Metrics

No related articles found.

Google Scholar

Cited By...

EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses

Google Scholar

Oral - PhysicianPharm

Study evaluating the prognostic value of PET parameters after 177Lu-DOTATATE Peptide Receptor Therapy in NET patients
Feasibility of Machine Learning-Assisted Personalized Dosimetry for Targeted Radioimmunotherapy with Anti-CD45 Iodine (¹³¹I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia; a Phase III Clinical trial
Volumetric evaluation of ^99mTc-pyrophosphate SPECT/CT in patients with transthyretin cardiac amyloidosis: optimization and correlation with cardiac functional parameters

Show more Oral - PhysicianPharm

Advances in Clinical Neuroimaging

¹⁸F-MK6240 longitudinal tau PET in ageing and Alzheimer's disease
Neuroinflammation in Semantic Variant Primary Progressive Aphasia

Show more Advances in Clinical Neuroimaging

Main menu

User menu

Search

Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma

Article Information

Author Information

Statistics from Altmetric.com

Cited By...

Article usage

Article usage: May 2021 to February 2025

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Oral - PhysicianPharm

Advances in Clinical Neuroimaging

Similar Articles